All News

I trained as a journalist and worked at news organizations where all the reporters wanted to cover politics and crime.

In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.

28 May 2009

28 May 2009

1 June 2009

Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.

21 May 2009

Neil Darwent and Roger Cooper of GSK Biologicals talk to Pharm Exec Europe about the company's new, state-of-the-art approach to clinical trials in Africa.

US pharma CEO salaries are still dwarfing the earnings of their European counterparts, but, with the industry and the economy currently in crisis, Jacky Law asks how long this can continue.

Cancer patients worry not only about their disease, but also the side effects of the drugs they take to treat it. Now the Centers for Disease Control and Prevention and biologics firm Amgen are partnering on a multi-prong program to get patients to pay attention to another, related, danger: chemo-related infections.

You know those loud soundtracks and distracting visuals during the safety information in your TV ads? Critics have been complaining about them, and new draft guidance from FDA is calling them a "no-no."

Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.

Defining, evaluating, and utilizing the Target Product Profile.

As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.

Interstitial Page

New prescriptions for antiviral treatments get huge boost due to H1N1 epidemic. Numbers exceed those seen during this year's influenza season, and the numbers are climbing.

As the economy continues to retract, fewer biotech companies are finding the funding they need to survive, driving more firms to sell or close shop.

Our 3-D cover jumps off the page. But the real question for us (and for you) is how do we get everything else to connect?

As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic.

Ortho-McNeil is reaching out to the adult ADHD segment through the popular social networking site. The plan is to grow followers through education and unbranded information. Pharm Exec takes a look at the new site.

News of the potential Solvay sale has sent the company's stock soaring, but is it good news for Belgium? Reflector reports.

Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.

The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.

Companies are fighting for strong relationships with key opinion leaders-and Genentech is winning, hands down.

After last week’s flurry of FDA warning letters directed at companies marketing through search ads, industry is left wondering what can be done be done to target patients online?

Rather than ignore its aging mini-stroke medication Aggrenox, BI has shifted marketing to education by launching an unbranded site dedicated to informing sufferers about transient ischemic attacks, better known as TIA.

In an effort to realign its sales division to reflect the current pharma environment-smaller, faster, better-Johnson & Johnson is trimming its sales force.

Reflector points to a number of recent alarm signals that have seen European pharma move further towards dangerous territory.

Maureen Regan